Methotrexat Ebewe (Methotrexate)

Methotrexate is a folate antagonist that inhibits the enzyme dihydrofolate reductase. This blocks the formation of tetrahydrofolate, a co‑factor required for synthesis of purine nucleotides and thymidylate, thereby reducing DNA, RNA and protein production and limiting cell proliferation.

The dosage of Methotrexat Ebewe is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. No standard dose is provided here.

Methotrexat Ebewe is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Methotrexat Ebewe shares the same mechanism of action as other folate antagonists such as pemetrexed, but methotrexate is more widely used for autoimmune diseases and a broader range of hematologic malignancies. Its oral formulation offers convenience, whereas some alternatives are only available intravenously.

Methotrexat Ebewe should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight to maintain stability.

Methotrexat Ebewe is taken orally as a tablet, usually with a full glass of water. Depending on the prescribing regimen, it may be taken once weekly or as directed by the healthcare professional. Patients should follow the prescriber’s instructions regarding timing and any required folic acid supplementation.

The most serious adverse events include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and acute renal failure. Early detection through regular laboratory monitoring is essential to mitigate these risks.

Methotrexat Ebewe is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, patients with known hypersensitivity to methotrexate or its excipients, and those receiving live vaccines. Caution is also advised for patients with pre‑existing blood disorders or uncontrolled infections.